Table 5.
Relationship between patient satisfaction and disease- and treatment-related information received
| n | Effectiveness | Adverse events | Cost | Convenience | ||
|---|---|---|---|---|---|---|
| Mean (SD) | Mean (SD) | Mean (SD) | Mean (SD) | Mean (SD) | ||
| Before starting the treatment, did your doctor speak to you about the disease? | ||||||
| Yes, at length | 112 | 76.34 (17.6) | 69.91 (36.35) | 40.0 (25.86) | 86.74 (13.10) | 79.63 (15.12) |
| Yes, a little | 14 | 62.50 (17.84) | 77.86 (31.85) | 33.2 (25.91) | 82.50 (8.03) | 72.14 (15.65) |
| p value1) | 0.002 | 0.446 | 0.272 | 0.050 | 0.108 | |
| Did your doctor speak to you about the different possible treatments for your disease? | ||||||
| Yes, at length | 100 | 76.70 (17.56) | 70.40 (36.57) | 40.45 (26.45) | 87.70 (12.50) | 78.85 (15.73) |
| Yes, a little | 25 | 69.40 (17.52) | 68.80 (36.15) | 35.20 (23.07) | 80.00 (11.99) | 77.72 (16.20) |
| p value1 | 0.012 | 0.959 | 0.577 | 0.007 | 0.491 | |
| Did your doctor speak to you about the characteristics of GRAZAX®? | ||||||
| Yes, at length | 105 | 76.33 (18.00) | 68.62 (37.65) | 39.38 (26.47) | 87.57 (12.39) | 78.84 (15.95) |
| Yes, a little | 20 | 69.50 (15.30) | 77.75 (28.07) | 39.50 (22.59) | 78.75 (12.23) | 77.50 (15.09) |
| p value1 | 0.023 | 0.904 | 0.460 | 0.008 | 0.237 | |
1The p value was calculated using the bilateral ANOVA parametric test (or nonparametric Kruskal–Wallis) with a 95% confidence level